More than 73% of US adults have obesity or overweight,1 incurring approximately $173 billion in associated medical costs annually.2 Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) substantially lower weight,3,4,5,6,7 hemoglobin A1c levels, and cardiovascular risk,8 trials suggest they must be continued for sustained effects.9,10. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.